About Rythm
Rythm sells a monthly blood test that people take at home. Members stick a small Tasso+ collection device on their upper arm, fill a tube and mail it back overnight. Rythm tests the sample in its own certified lab. Results for more than 25 markers, such as hormones, cholesterol and iron, appear in an app with an AI coach.
Rythm is based in San Francisco and hires its lab staff in Omaha, Nebraska. Co-founder Robby Wade is CEO and co-founder Dacri Burdan is CTO. A test costs $79 a month, and members can skip months or cancel. Diplo, Jesse Itzler, Sara Blakely and Odell Beckham Jr. appear in its marketing. Rythm has delivered more than 10 million results.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Jun 5, 2026 | Jun 18, 2026 | $31,078,122fully sold | 8 | $3.8M | EquityRule 506(b) | Form D ↗ |
| Oct 30, 2025 | Nov 13, 2025 | $19,337,790of $20.7M target | 18 | $1.0M | EquityRule 506(b) | Form D ↗ |
| May 30, 2025 | Jun 2, 2025amended Jun 17, 2025 | $5,482,332fully sold | 27 | $203K | EquityRule 506(b) | Form D/A ↗1 earlier filing |
| Total, three offerings | $55,898,244 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Rounds announced by Rythm
What the company said publicly about its funding. Announced amounts can differ from Form D figures: an announcement can combine several closings, and some money is raised without a Form D.
| Announced | Round | Amount | Investors | Source |
|---|
Why Investors Backed Rythm
Investors backed Rythm on a simple idea: people will test their blood every month if it is easy enough. Members collect a small sample at home, mail it overnight and read the results in an app. Rythm runs the tests in its own lab, so it controls each step from kit to result. Collaborative Fund, one of its backers, points to a large consumer need for health tracking that "sick care" does not meet.
The problem it targets
Rythm's view is that a single lab test is only a snapshot, so it can miss long-term trends. Most blood testing companies charge $500 or more for a single test. At Collaborative Fund's 2025 annual meeting, CEO Robby Wade put it bluntly: "Your doctor's job is not to optimize your health. Their job is to provide sick care." Collaborative Fund called that unmet need "the core insight driving our investment thesis in biomarkers and personalized health."
What the product does
Each month, Rythm ships a kit with a Tasso+, an FDA-cleared device that sticks to the upper arm. A tiny lancet inside draws blood into a standard tube, which members return by overnight FedEx. Rythm's own CLIA-certified, CAP-accredited lab runs the tests on Roche and Sysmex analyzers. The panel covers more than 25 markers, from testosterone and thyroid hormones to ApoB, vitamin D and kidney function. Results reach the app within three business days of the sample's arrival. An AI coach then explains them. Members pay $79 per test every 30 days.
Progress so far
Rythm has not published revenue or member numbers. Rythm has delivered more than 10 million results and holds a 4.8-star rating from over 3,000 reviews. It has processed millions of tests across all 50 states. Business Insider reports that Diplo, Jesse Itzler and Sara Blakely are brand ambassadors. In May 2026, STAT described Wade running a blood draw for about 100 people at the Vitalist Bay longevity conference in Berkeley. In October 2026, Rythm listed 11 open jobs, including four lab roles in Omaha.
Who backs it
Rythm has not announced its rounds or named a lead investor. Several firms list it on their own sites, however. Collaborative Fund named Rythm among the companies it backed in 2025. Courtside Ventures lists it as a seed investment from its fourth fund. Acre Venture Partners also lists Rythm, and Coefficient Capital, a New York consumer investor, shows it as a new investment. Andrew Goletka, a managing partner at Coefficient, is a Rythm director.
How the market is moving
Money keeps flowing into consumer blood testing. Function raised $450 million from General Catalyst in July 2026, Athletech News reported. Investors had valued it at $2.5 billion in 2025, and it has more than 500,000 members. In April 2026, Function bought Getlabs, which sends phlebotomists to people's homes. Hims & Hers bought Trybe Labs in early 2025, and Business Insider says it paid $153 million for YourBio Health, a Tasso rival. Jefferies bankers estimated in September that global at-home testing could be worth $67 billion by 2030, according to Business Insider.
We wrote this summary from public statements by Rythm and its investors. It is not investment advice.
Rythm in the News
Leadership Team
Executive officers and directors listed on Rythm's Form D filed Jun 18, 2026.
Earlier filings also listed Andrew Montgomery (director, last listed Nov 2025).
Sources
- SECRythm Health, Inc. Form D, filed Jun 2, 2025
- SECRythm Health, Inc. filing history
- Companyrythmhealth.com, The Rythm Lab (about and team)
- Companyrythmhealth.com, FAQ
- Companyrythmhealth.com, What we test (biomarker panel)
- Companyrythmhealth.com, Inside the Rythm Laboratory (2026-08-13)
- Companyrythmhealth.com, Meet Tasso+ (2026-08-13)
- Companyrythmhealth.com, How Is Rythm Different From Theranos? (2026-08-13)
- Companyrythmhealth.com, privacy policy (legal name and address)
- Companyrythmhealth.com, terms of service (legal name and address)
- CompanyRythm Health careers page (Workable)
- Investorcollabfund.com, 8 Highlights from Collaborative Fund's 2025 Annual General Meeting (2025-11-14)
- InvestorCollaborative Fund 2025 Year in Review, by Craig Shapiro (2026-01-11)
- Investorcourtsidevc.com, Rythm Health portfolio page (Fund IV, Seed)
- Investoracre.vc, home page portfolio list
- Investorcoefficientcap.com, home page (investments and team)
- PressAthletech News, Function raises $450M (2026-07-31)
- PressAthletech News, Function acquires Getlabs (2026-04-09)